Formycon AG (HAM:FYB) FFO


HAM:FYB Formycon AG HAM:FYB
64 GF Score
Price €18.86
GF Value €36.12
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Formycon AG FFO?

FFO (Funds from operations) only applies to REITs.

HAM:FYB
64GF Score
Formycon AG HAM:FYB
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Formycon AG (HAM:FYB) Overvalued in 2026?

Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued. The current stock price of €18.86 is trading 47.8% below its estimated GF Value™ of €36.12. GuruFocus considers Formycon AG to be Possible Value Trap.

Key valuation signals for HAM:FYB:

  • FFO:
  • GF Value™: €36.12 vs. price of €18.86 (47.8% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the HAM:FYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Formycon AG Business Description

Address Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
64GF Score

Get the complete analysis for HAM:FYB

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.86
Price
€36.12
GF Value